SUBSCRIBE
SUBSCRIBE

Brianna Abbott

Freelance writer

Brianna Abbott is a freelance writer for BioSpace. She is a seasoned healthcare reporter, covering cancer, infectious disease, the business of medicine and more. Brianna is based in Bristol, Rhode Island and can be reached at briabbott17@gmail.com.

Man hand with magnifying glass. Yellow ray coming from loupe. Conducting check, information search and analysis concept. Spy, accountant, auditor job in abstract style. High quality photo
Ovarian cancer
4 ovarian cancer candidates to watch: GSK, Allarity and more
Recent approvals for Corcept Therapeutics and Merck have injected momentum into the space, where GSK, Allarity Therapeutics, OSE Immunotherapies and others are advancing their own candidates.
June 29, 2026
 · 
6 min read
 · 
Brianna Abbott
New Year Direction Concept 2026 to 2033 and Sustainable Development Concept, Business Restart, Future Work 2026 to 2033 on Asphalt Road, Sunset Time at Destination
Cancer
ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come
Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data are expected later this year.
June 2, 2026
 · 
6 min read
 · 
Brianna Abbott
Chicago Cityscape at Sunset with Lakefront View. Aerial view of Chicago skyline at sunset, showing Lake Michigan shoreline, tree-lined parks, and a busy roadway along the waterfront
Cancer
ASCO: A battle of bispecifics, Eli Lilly’s big win and more
Practice-changing data in lung cancer, prostate cancer and more were on display over the weekend at the American Society of Clinical Oncology annual meeting in Chicago. Plus, early readouts on assets that could reshape the cancer landscape.
June 1, 2026
 · 
4 min read
 · 
Brianna Abbott
Office worker trapped in a maze. Workaholic, social isolation concept. Digital 3D rendering.
Pancreatic cancer
ASCO: Revolution poised to capture RAS space as pancreatic cancer dataset ‘derisks’ approval
Revolution Medicines and its RAS inhibitor daraxonrasib stole the show at the American Society of Clinical Oncology’s annual meeting this weekend, as Truist Securities predicts a possible third quarter launch for the pancreatic cancer drug.
June 1, 2026
 · 
3 min read
 · 
Brianna Abbott
Chicago Cityscape at Sunset with Lakefront View. Aerial view of Chicago skyline at sunset, showing Lake Michigan shoreline, tree-lined parks, and a busy roadway along the waterfront
Cancer
All eyes on Revolution, bispecific antibodies and more at ASCO26
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.
May 26, 2026
 · 
6 min read
 · 
Brianna Abbott